Stryker (SYK) Earnings Date & Reports

Key Takeaways

• Stryker Corporation (NYSE: SYK) is expected to report third-quarter 2026 results on October 29, 2026, after the market close.
• Wall Street consensus calls for adjusted earnings per share (EPS) of roughly $3.58 and revenue near $6.67 billion for the September quarter.
• Those expectations imply healthy year-over-year growth, building on a strong second quarter that saw organic sales rise 9% and adjusted EPS beat estimates.
• Full-year 2026 guidance of 8.3% to 9.3% organic sales growth and $14.95 to $15.10 in adjusted EPS will be a central focus of the report.
• Investor sentiment has cooled despite solid fundamentals, with several analysts trimming price targets on margin concerns heading into the print.

Earnings Context and Why It Matters

Stryker is one of the world's largest medical technology companies, spanning orthopedics, medical-surgical equipment, and neurotechnology. Its quarterly earnings serve as a key health check on procedure volumes, hospital capital spending, and demand for elective surgery globally. The report arrives against a backdrop of strong underlying demand but growing scrutiny of margins. In the second quarter, Stryker delivered an adjusted EPS beat and 9% organic growth, yet the stock still fell after hours as investors weighed the limits of its narrowed full-year outlook. The third-quarter release will test whether the company can maintain its growth trajectory while defending profitability and reassure a market that has grown cautious about medical device valuations.

Earnings Expectations

For the third quarter ending September 30, 2026, analysts project adjusted EPS of approximately $3.58, according to consensus data, with individual estimates ranging from roughly $3.44 to $3.80. Revenue is expected to come in near $6.67 billion, up about 10% from the $6.06 billion reported in the same period a year earlier. These figures would mark a return to steady growth following a first quarter in which Stryker missed expectations with adjusted EPS of $2.60 and revenue growth of just 2.6%, partly reflecting the lingering effects of a cybersecurity incident earlier in the year.

Investors will also watch organic sales growth, a measure that strips out the impact of acquisitions and currency movements. Management has guided to 8.3% to 9.3% organic growth for the full year, and the third-quarter figure will signal whether that target remains achievable. On profitability, the company's adjusted operating margin expanded 170 basis points to 27.4% in the second quarter, and any commentary on sustaining that level will matter. Notably, Stryker historically has beaten consensus EPS estimates in most recent quarters, but the stock's reaction has not always been positive, underscoring how much weight the market places on forward guidance.

AI Screener

For investors looking to cut through the noise ahead of earnings season, Tickeron's AI Screener offers a data-driven way to scan the market. This AI-powered stock and ETF discovery tool helps traders and investors filter thousands of securities based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can customize their search using filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. Explore the AI Screener to refine your watchlist before Stryker's next report.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report has been mixed. After a strong second-quarter beat, Stryker shares dropped about 9% in after-hours trading, and the stock has continued to drift lower in the months since. This reflects investor frustration that the company's narrowed full-year guidance left limited room for upside, even as results topped expectations. Several Wall Street firms have trimmed their price targets recently, citing margin pressures, softer growth assumptions in hips and knees, and ongoing headwinds in the peripheral vascular business. Still, many analysts retain constructive ratings, viewing Stryker's diversified portfolio and robotics franchise as durable growth engines. The key risk entering the print is that guidance or margin commentary disappoints again, which could extend the stock's recent pullback even if headline results beat consensus.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, investors should focus on several themes that will shape Stryker's outlook for the remainder of 2026 and into 2027.

First is the sustainability of organic growth. Management's 8.3% to 9.3% full-year target implies a meaningful acceleration in the second half, so the third-quarter organic sales rate will be closely compared against that bar. Slower-than-expected growth in hips, knees, or the peripheral vascular segment would raise questions about whether the target is achievable.

Second is margin execution. The second quarter benefited from tariff reversals and lower inventory step-up amortization, both of which are non-recurring. Investors will want to see whether core operating margins can hold near recent levels without those tailwinds, especially as the company continues to invest in its Mako robotic surgery platform and other growth initiatives.

Finally, watch for any updates to full-year adjusted EPS guidance of $14.95 to $15.10 and commentary on hospital capital spending, supply-chain stability, and the lingering costs of the earlier cybersecurity incident. These factors will determine whether Stryker can convert solid demand into durable earnings growth and regain investor confidence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations